SEC Form 4 · accession 0001443841-26-000007
Indivior Pharmaceuticals, Inc. · INDV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Ciaffoni
Officer — Chief Executive Officer · Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 23, 2026 · 5:24 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001625297
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 22, 2026 | M | 1,266,903 | — | A | 1,402,879 | D | |
| Common StockF3 | Jun 22, 2026 | F | 612,549 | $38.32 | D | 790,330 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock UnitsF2,F1 | — | Jun 22, 2026 | M | 1,266,903 | D | — | — | Common Stock | 1,266,903 | 0 | D |
Explanation of responses
- F1Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026.
- F2Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3Shares withheld to satisfy tax withholding obligations associated with the vesting of performance stock units on June 22, 2026.